Visit uBiome

The company raised $83 million through the combination of Series C1, Series C2 and Series C3 venture funding in a deal led by OS Fund on September 21, 2018, putting the company's post-money valuation at an estimated $600 million. DNA Capital, 8VC, Dentsu Ventures, 11.2 Capital, Y Combinator, family offices, Collaborative Fund, Harmony Partners and other undisclosed new and existing investors also participated in the round. The company has now raised $105 million in total financing to date. The company intends to use the funds to enhance and expand its product portfolio, leverage insights gained by building a large microbiome database to expand into drug research and development using pre-existing patent assets and industry research collaborations, not data sales, accelerate and expand commercialization of SmartGut, SmartJane, Explorer and other clinical tests under development, including companion diagnostics and begin commercialization of biopharma molecules and live biotherapeutics based on mining of existing IP.